Zhang X, Collins L, Fabre J W
Department of Clinical Sciences, Institute of Liver Studies, King's College Hospital, Guy's, King's and St Thomas' School of Medicine, London, UK.
J Gene Med. 2001 Nov-Dec;3(6):560-8. doi: 10.1002/jgm.224.
Following receptor-mediated endocytosis, vector/DNA complexes require assistance to exit endocytic vesicles in order to avoid degradation in the lysosomes. Overcoming this barrier is a major challenge for the development of receptor-targeted, non-viral gene delivery.
The fusogenic peptide of influenza virus haemagglutinin, lipofectamine and chloroquine were tested singly and in combination in various doses for promoting in vitro gene transfer by an integrin-targeted, non-viral DNA vector (polylysine-molossin).
The fusogenic peptide and lipofectamine both individually promoted integrin-targeted gene delivery. However, the combined use of these agents was particularly effective, even at concentrations where neither agent singly had any effect on promoting gene delivery by polylysine-molossin. This optimal combination was effective on several cell lines and primary cell cultures. On the HuH7 cell line, it was approximately five-fold more effective than optimal chloroquine concentrations for integrin-targeted gene delivery and four to five times more effective than commercially available polyethylenimine. With the beta-galactosidase reporter gene, 60-65% of HepG2 cells and 75-80% of HuH7 cells were positive. The surface charge of polylysine-molossin/DNA/lipofectamine/fusogenic peptide complexes was approximately the same as that of polylysine-molossin/DNA complexes. The size distribution of the complexes suggested that competitive binding of polylysine-molossin and lipofectamine to DNA influenced the overall efficacy of this approach.
Although the mechanisms are not clear, the combined use of very low doses of two membrane-destabilizing agents results in high levels of receptor-targeted gene delivery.
在受体介导的内吞作用之后,载体/DNA复合物需要帮助才能离开内吞小泡,以避免在溶酶体中降解。克服这一障碍是受体靶向性非病毒基因递送发展的主要挑战。
对流感病毒血凝素的融合肽、脂质体转染试剂和氯喹进行了单独及不同剂量组合的测试,以促进一种整合素靶向性非病毒DNA载体(聚赖氨酸-桑寄生凝集素)的体外基因转移。
融合肽和脂质体转染试剂各自都能促进整合素靶向性基因递送。然而,这些试剂的联合使用特别有效,即使在单独使用时两种试剂对聚赖氨酸-桑寄生凝集素促进基因递送均无任何作用的浓度下也是如此。这种最佳组合对几种细胞系和原代细胞培养均有效。在HuH7细胞系上,它对整合素靶向性基因递送的效果比最佳氯喹浓度高约五倍,比市售聚乙烯亚胺高四至五倍。使用β-半乳糖苷酶报告基因时,60 - 65%的HepG2细胞和75 - 80%的HuH7细胞呈阳性。聚赖氨酸-桑寄生凝集素/DNA/脂质体转染试剂/融合肽复合物的表面电荷与聚赖氨酸-桑寄生凝集素/DNA复合物的表面电荷大致相同。复合物的大小分布表明,聚赖氨酸-桑寄生凝集素和脂质体转染试剂与DNA的竞争性结合影响了该方法的整体效果。
虽然机制尚不清楚,但两种极低剂量的膜去稳定剂联合使用可导致高水平的受体靶向性基因递送。